Professor Chng is the Director of the National University Cancer Institute, Singapore (NCIS). Prof Chng obtained his medical degree from the University of Leeds, UK, and did his internal medicine residency in the United Kingdom. Fellowship training in haematology was completed in Singapore before he obtained an A*STAR international fellowship (2004) to go to the Mayo Clinic for a research fellowship in multiple myeloma genetics. His current research is very translational and involves the use of high-resolution global genomic technique to understand biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies, with the aim of improving patient’s outcome and personalizing treatment. At Invitrocue, Prof Chng provides an updated and pragmatic view of the methodological processes and implementation considerations in the clinical adoption of in vitro experimental patient-derived models for multiple myeloma and lymphoma.

  Myeloma and lymphoma, personalizing treatment, biology, identify drug targets, understand drug resistance and improve disease prognosis in haematological malignancies,